Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Multi-center Randomized, Double-blind and Positive-controlled Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

NCT06241755 is registered in ClinicalTrials.gov with Chengdu CoenBiotech Co., Ltd as lead sponsor.

NCT NCT06241755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06241755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Multi-center Randomized, Double-blind and Positive-controlled Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Lead sponsor
Chengdu CoenBiotech Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
December 28, 2023
Completion date
September 3, 2026
Enrollment
412 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer